UPDATE: UBS Downgrades Celgene (CELG) to Neutral: Taking Some Off The Table

September 10, 2012 8:19 AM EDT
Get Alerts CELG Hot Sheet
Price: $113.62 -1.39%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade CELG Now!
Join SI Premium – FREE
(Updated - September 10, 2012 12:26 PM EDT)

UBS downgraded Celgene (NASDAQ: CELG) from Buy to Neutral. PT raised $2 to $80.

Analyst, Matthew Roden, said, "CELG shares are up 27% since Revlimid was not approved in the EU (S&P: +8%), at which time we argued upcoming apremilast data represented a catalyst for re-rating. That having played out, we see the risk-reward as more balanced at current levels, and view CELG as a stock we’d rather add on pullbacks, such as those created from the second cancer controversy or the Revlimid EU non-approval. See our accompanying industry note for our updated views on the sector."

FY13 EPS estimate lowered from $5.53 to $5.46.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $75.44 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades

Related Entities

UBS, Standard & Poor's

Add Your Comment